BSPK — what changed in the latest 10-Q
A section-by-section comparison of BSPK's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2025-11-12 vs the prior 10-Q · 2025-08-27
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +17 | −13 | ~2 | 7 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 7 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2025-11-12
Results of Operations for the three months ended September 30, 2025 and September 30, 2024
Sales during the three months ended September 30, 2025 were $467,945 compared to $277,471 for the three months ended September 30, 2024. The increase in sales was a result of increased product sales of pre-rolled joints to licensed dispensaries in Colorado as well as increased joint production servi…
Cost of goods sold for the three months ended September 30, 2025 was $233,770 compared to $162,476 for the three months ended September 30, 2024. The increase was a direct result of the increase in sales. The increase in cost of sales was due to increases in purchases of raw materials, packaging, an…
Selling, general and administrative expenses for the three months ended September 30, 2025 and September 30, 2024 were $260,228 and $361,393, respectively. The decrease was mainly attributable to stock-based compensation of $10,496 for the three months ended September 30, 2025 compared to $47,679 fo…
Results of Operations for the nine months ended September 30, 2025 and September 30, 2024
Text removed vs the prior filing · source: 10-Q · 2025-08-27
Beginning January 1, 2025, we rebranded our product offerings in Colorado as The Joint Company.
Results of Operations for the three months ended June 30, 2025 and June 30, 2024
Sales during the three months ended June 30, 2025 were $390,553 compared to $278,163 for the three months ended June 30, 2024. The increase in sales was a result of increased product sales of pre-rolled joints to licensed dispensaries in Colorado as well as increased joint production services for th…
Cost of goods sold for the three months ended June 30, 2025 was $193,054 compared to $172,046 for the three months ended June 30, 2024. The increase was a direct result of the increase in sales. The increase in cost of sales was due to increases in purchases of raw materials, packaging, and labor as…
Selling, general and administrative expenses for the three months June 30, 2025 and June 30, 2024 were $337,625 and $325,885, respectively. The decrease was mainly attributable to stock-based compensation of $0 for the three months ended June 30, 2025 compared to $59,855 for the three months ended J…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice